Wall Street Zen Upgrades Lite Strategy (NASDAQ:LITS) to Hold

Key Points

• Wall Street Zen has upgraded Lite Strategy (NASDAQ:LITS) from a "sell" rating to a "hold" rating, reflecting a more favorable view of the stock.
• Despite the upgrade, Weiss Ratings maintains a "sell (d-)" rating for Lite Strategy, indicating mixed opinions from analysts regarding the company's performance.
• As of the latest trading session, LITS stock is priced at $2.56, with a 52-week range of $1.46 to $9.00, highlighting its volatility in the market.

Lite Strategy (NASDAQ:LITS - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Friday.

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Lite Strategy in a report on Saturday, September 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of "Sell".

Lite Strategy Price Performance

LITS stock traded down $0.12 on Friday, reaching $2.56. The company's stock had a trading volume of 1,507,643 shares, compared to its average volume of 1,740,819. Lite Strategy has a 52 week low of $1.46 and a 52 week high of $9.00.

About Lite Strategy

MEI Pharma, Inc, a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.